N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese

Oral Diseases

Volumn 18, Issue 8, 2012, Pages 741-747

  Zhong, Y ^a   Wu, Y ^a   Li, C ^a   Tang, J ^a   Wang, X ^b   Ren, G ^a   Carr, A ^c   Perez R ^c   Guo, W ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

N Glycolyl GM3 ganglioside; Oral mucosal melanomas

Indexed keywords

GANGLIOSIDE GM3; MESSENGER RNA;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELL MEMBRANE; CHINESE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MELANOMA; MELANOMA CELL; ORAL MUCOSAL DISEASE; ORAL MUCOSAL MELANOMA; PIGMENTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL MEMBRANE; CHINA; CYTOPLASM; FEMALE; G(M3) GANGLIOSIDE; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEVUS, PIGMENTED;

EID: 84866866591     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2012.01939.x     Document Type: Article

References (33)

1. Blanco R, Rengifo E, Cedeño M, Rengifo CE, Alonso DF, Carr A (2011). Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol2011: 1-10, 645641.
2. Carr A, Mullet A, Mazorra Z et al (2000). A mouse IgG 1 monoclonal antibody specific for N-Glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma19: 241-247.
3. Carr A, Mesa C, del Carmen Arango M, Vázquez AM, Fernández LE (2002). In vivo and in vitro anti-tumor effect of 14F7monoclonal antibody. Hybrid Hybridomics21: 463-468.
4. Carr A, Rodriguez E, Arango MC et al (2003). Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol21: 1015-1021.
5. Chang KW, Lin SC, Chao SY, Kwan PC, Chiu CP, Wong YK (2001). Establishment and characterization of an oral melanoma cell line (ME). Oral Oncol37: 301-307.
6. van Cruijsen H, Ruiz M, van der Valk P, de Gruijl TD, Giaccone G (2009). Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer9: 1-9, article no. 180
7. Fernández LE, Alonso DF, Gomez DE, Vázquez AM (2003). Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev Vaccines2: 817-823.
8. Garzino-Demo P, Fasolis M, Maggiore GML, Pagano M, Berrone S (2004). Oral mucosal melanoma: a series of case reports. J Craniomaxillofac Surg32: 251-257.
9. Hakomori S (1989). Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res52: 257-331.
10. Kawachi S, Saida T (1992). Analysis of the expression of Hanganutziu-Deicher (HD) antigen in human malignant melanoma. J Dermatol19: 827-830.
11. Labrada M, Clavell M, Bebelagua Y et al (2010). Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther10: 153-162.
12. de León J, Fernández A, Clavell M et al (2008). Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25 - effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol20: 591-600.
13. de Leòn J, Fernández A, Mesa C, Clavel M, Fernández LE (2006). Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother55: 443-450.
14. Livingston PO, Zhang S, Lloyd KO (1997). Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother45: 1-9.
15. Malykh YN, Schauer R, Shaw L (2001). N-Glycolylneuraminic acid in human tumours. Biochimie83: 623-634.
16. Marquina G, Waki H, Fernandez LE et al (1996). Gangliosides expressed in human breast cancer. Cancer Res56: 5165-5171.
17. Meleti M, Leemans CR, Mooi WJ, Vescovi P, van der Waal I (2007). Oral malignant melanoma: a review of the literature. Oral Oncol43: 116-212.
18. Mulens V, de la Torre A, Marinello P et al (2010). Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: results from a controlled study in metastatic breast cancer patients. Hum Vaccin6: 1-9 [Epub ahead of print].
19. Nakarai H, Chandler PJ, Kano K, Morton DL, Irie RF (1990). Hanganutziu-Deicher 8 HD) antigen as a possible target for immunotherapy of melanoma. Int Arch Allergy Appl Immunol91: 323-328.
20. Oliva JP, Valdés Z, Casacó A et al (2006). Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)TcBreast. Cancer Res Treat96: 115-121.
21. Osorio M, Gracia E, Rodríguez E et al (2008). Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther7: 488-495.
22. Owens JM, Roberts DB, Myers JN (2003). The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg129: 864-868.
23. Patel SG, Prasad ML, Escrig M (2002). Primary mucosal malignant melanoma of the head and neck. Head Neck24: 247-257.
24. Patrick RJ, Fenske NA, Messina JL (2007). Primary mucosal melanoma. J Am Acad Dermatol56: 828-834.
25. Roque-Navarro L, Chakrabandhu K, de León J et al (2008). Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther7: 2033-2041.
26. Rosenberg SA (2001). Progress in human tumour immunology and immunotherapy. Nature411: 380-384.
27. Schlenzka W, Shaw L, Kelm S et al (1996). CMP-N-acetylneuraminic acid hydroxylase: the first cytosolic Rieske iron-sulphur protein to be described in Eukarya. FEBS Lett385: 197-200.
28. Scursoni AM, Galluzzo L, Camarero S et al (2010). Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry. Pediatr Dev Pathol13: 18-23.
29. Scursoni AM, Galluzzo L, Camarero S et al (2011). Detection of N-Glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol2011: 245181.
30. Tangvoranuntakul P, Gagneux P, Diaz S et al (2003). Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Nat Acad Sci USA100: 12045-12050.
31. Thompson LD, Wieneke JA, Miettinen M (2003). Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol27: 594-611.
32. Zhang S, Cordon Cardo C, Zhang HS et al (1997). Selection of carbohydrate tumor antigen as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer73: 42-49.
33. Vázquez AM, Alfonso M, Lanne B et al (1995). Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma14: 551-556.